MULTI DRUG RESISTANT TUBERCULOSOS IN THE COUNTRIES OF THE OUTER WORLD AND IN THE RUSSIANFEDERATION
https://doi.org/10.21292/2075-1230-2017-95-11-5-17
Abstract
The article presents information on the prevalence of tuberculosis with MDR/RR/XDR in different countries and the WHO regions in comparison with the Russian Federation, given in the WHO Global Reports on Tuberculosis, and the interpretation and systematization of data presented in the WHO publications.
The issues of the WHO estimations of MDR/RR/XDR TB prevalence and incidence rates, the role of drug resistance sample survey and continuous MDR TB surveillance system in obtaining both qualitative data on registered cases of MDR/RR/XDR TB and adequate estimations of relevant indicators are considered.
The article provides basic information on the evaluation and registration of cases of MDR/RR/XDR TB in the countries of the world, the WHO regions and in the world at large.
The data given in the article include information on the coverage and effectiveness of treatment of patients with MDR/RR/XDR TB.
About the Authors
I. А. Vаsilyevа
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Irina A. Vasilyeva –Doctor of Medical Sciences, Professor, Director
4, Dostoevsky St., Moscow, 127473
E. M. Belilovsky
Moscow Municipal Scientific Practical Center of Tuberculosis Control
Russian Federation
Russian Federation
Evgeny M. Belilovsky – Candidate of Biological Sciences, Head of Deparment.
10, Stromynka St., Moscow, 107014
S. E. Borisov
Moscow Municipal Scientific Practical Center of Tuberculosis Control
Russian Federation
Russian Federation
Sergey E. Borisov – Doctor of Medical Sciences, Professor
10, Stromynka St., Moscow, 107014
S. А. Sterlikov
Central Research Institute for Public Health Organization and Informatization
Russian Federation
Russian Federation
Sergey A. Sterlikov –Doctor of Medical Sciences
11, Dobrolyubova St., Moscow, 127254.References
1. Vassilyeva I.A., Belilovsky E.M., Borisov S E., Sterlikov S.A. Global Reports of the World Health Organization on tuberculosis: formation and interpretation. TB and lung diseases – 2017. – Т. 95, № 5. – С. 7-16.
2. Cultural methods of diagnostics of tuberculosis. Training aid, basic course of training for specialists of bacteriological laboratories of tuberculosis control institutions ‒ М., 2008. ‒ 208 p.
3. Anti-tuberculosis Drug Resistance in the world. Report № 3. WHO. Geneva, 2004. ‒ P. 300.
4. Borisov S. E., Dheda K., Enwerem M. et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study // Eur. Respir. J. ‒ 2017. ‒ Vol. 49: 1700387.
5. Caminero J. A., Piubello A., Scardigli A. et al. Proposal for a standardized treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases // Eur. Respir. J. – 2017. – Vol. 50, № 1: 1700648 [https://doi.org/10.1183/13993003.00648-2017].
6. Chee Cynthia B. E., KhinMar Kyi-Win, Sng Li-H., The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? // Eur. Respir. J. – 2017. – Vol. 50, № 2. – 1700753. doi: 10.1183/13993003.00753-2017.
7. Dietze R., Hadad D. J., McGee B. et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis // Am. J. Respir. Crit. Care. Med. – 2008. – Vol. 178, № 11. – P. 1180-1185. doi: 10.1164/rccm.200806-892OC.
8. Falzon D., Gandhi N., Migliori G. B. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes // Eur. Respir. J. – 2013. – Vol. 42, № 1. – P. 156-168. doi: 10.1183/09031936.00134712.
9. Global tuberculosis control: WHO report 2011, WHO/HTM/TB/2011.16, 246 p.
10. Global Tuberculosis Report 2013, WHO/HTM/TB 2013.11.
11. Global tuberculosis report, 2016, WHO, WHO/HTM/TB/2016.13, 214 p.
12. Hewison C., Ferlazzo G., Avaliani Z. et al. Six-Month Response to Delamanid Treatment in MDR TB Patients // Emerg. Infect. Dis. – 2017. – Vol. 23, № 10. – P. 1746-1748. doi: 10.3201/eid2310.170468.
13. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO=HTM/TB/2010.3.
14. Pym A. S., Diacon A. H., Tang S.-J. et al. Bedaquiline in the treatment of multidrug- and extensively drug resistant tuberculosis //Eur. Respir. J. – 2016. – Vol. 47, № 2. – P. 564–574. DOI: 10.1183/13993003.00724-2015.
15. Skripconoka V., Danilovits M., Pehme L. et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis // Eur. Respir. J. – 2013. – Vol. 41, № 6. – P. 1393–1400. DOI: 10.1183/09031936.00125812/
16. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis. WHO, 2010
17. van der Werf M. J., Hollo V., Ködmön C. et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union // Eur. Respir. J. – 2017. – Vol. 49, № 3: 1601992 [https://doi.org/ 10.1183/13993003.01992-2016].
18. WHO's global TB database http://www.who.int/tb/country/data/download/en/ (Date of application: 01.10.2017).
19. World Health Organization: Anti-tuberculosis drug resistance in the world: Report Number 4. The WHO/IUALTD global project on anti-tuberculosis drug resistance surveillance // WHO/HTM/TB/2008.394. Geneva: WHO. 2008.
Review
For citations:
Vаsilyevа I.А., Belilovsky E.M., Borisov S.E., Sterlikov S.А. MULTI DRUG RESISTANT TUBERCULOSOS IN THE COUNTRIES OF THE OUTER WORLD AND IN THE RUSSIANFEDERATION. Tuberculosis and Lung Diseases. 2017;95(11):5-17. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-11-5-17
Views:
2195
Email this article 